Evaluation of the latent tuberculosis screening and treatment strategy for asylum seekers in Stockholm, Sweden 2015-2018: a record linkage study of the care cascade.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
03 2021
Historique:
received: 26 02 2020
accepted: 12 08 2020
pubmed: 29 8 2020
medline: 3 7 2021
entrez: 29 8 2020
Statut: epublish

Résumé

About 90% of active tuberculosis (TB) cases in Sweden are foreign born and are mainly due to latent TB infection (LTBI) reactivation. The aim of this study was to assess the current migrant LTBI screening programme with regards to test results and completion of the care cascade. A retrospective cohort of all 14173 individuals attending a health examination was established for the Stockholm Region 2015-2018 through record-linkage of data extracted from the Swedish Migration Authority and medical records. Screening results, referrals to specialist care and treatment initiation were ascertained through automated data extraction for the entire cohort. Detailed cascade steps, including treatment completion, were analysed through manual data extraction for a subsample of all persons referred to specialist care in the period 2016-2017. Of 5470 patients screened with an interferon-gamma release assay (IGRA), 1364 (25%) were positive, of whom 358 (26%) initiated LTBI treatment. An increased trend in IGRA-positivity was seen for increased age and TB-incidence in country of origin. Among the IGRA positive patients, 604 (44%) were referred to specialist care. Lower age was the main referral predictor. In the subsample of 443 patients referred to specialist care in 2016-2017, 386 (87%) were invited, of whom 366 (95%) attended. Of 251 patients (69%) recommended for LTBI treatment, 244 (97%) started such treatment and of those 221 (91%) completed it. The low attrition in patient-dependent cascade steps shows that the voluntary approach works well. Low LTBI treatment attainment is due to the current conservative local treatment policy, which means the vast majority are IGRA-tested without an intention to treat for LTBI.

Identifiants

pubmed: 32855227
pii: 13993003.02255-2020
doi: 10.1183/13993003.02255-2020
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©ERS 2021.

Déclaration de conflit d'intérêts

Conflict of interest: J. Nederby Öhd has nothing to disclose. Conflict of interest: M-P. Hergens has nothing to disclose. Conflict of interest: Y. Luksha has nothing to disclose. Conflict of interest: C. Buxbaum has nothing to disclose. Conflict of interest: J. Shedrawy has nothing to disclose. Conflict of interest: J. Jonsson has nothing to disclose. Conflict of interest: J. Bruchfeld has nothing to disclose. Conflict of interest: K. Lönnroth has nothing to disclose.

Auteurs

Joanna Nederby Öhd (J)

Dept of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Dept of Communicable Disease Prevention and Control, Stockholm Region, Sweden.

Maria-Pia Hergens (MP)

Dept of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Dept of Communicable Disease Prevention and Control, Stockholm Region, Sweden.
Division of Infectious Diseases, Dept of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

Yauheni Luksha (Y)

Dept of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden.

Charlotte Buxbaum (C)

Astrid Lindgren Children's Hospital, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Jad Shedrawy (J)

Dept of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Jerker Jonsson (J)

Dept of Public Health Analysis and Data Management, Unit for Epidemiological Monitoring, Public Health Agency of Sweden, Solna, Sweden.

Judith Bruchfeld (J)

Division of Infectious Diseases, Dept of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Dept of Infectious Diseases, Karolinska University Hospital Solna, Stockholm, Sweden.

Knut Lönnroth (K)

Dept of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH